The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Bayer and Merck & Co need Vitality data to breathe life into vericiguat, while Akero awaits its first big test with the Nash project AKR-001.
In the battle between two Kit/PDGFRα kinase inhibitors first blood goes to Blueprint’s avapritinib.
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.